TET2 and chronic myelomonocytic leukemia: Three TET2MUT MDS/CMML patients were chosen based on a KIR2D expression on NK cells below 25%, and a TET2 mutation VAF superior to 40% in the cell bulk at diagnosis (TET2MUT KIRLOW patients: MUT22, MUT27, MUT33).